 SAN DIEGO HAYWARD, Calif.--BUSINESS WIRE--- ACRX ACELRX--Shareholder rights law firm Robbins LLP reminds investors that a class action has been filed on behalf of all purchasers of AcelRx Therapeutics, Inc. NASDAQ:ACRX securities between March 17, 2020 and February 12, 2021, against the Company for remedies under the Securities Exchange Act of 1934. AcelRx is a pharmaceutical company that develops and commercializes therapies for the treatment of acute pain. The Companys lead product candidate is DSUVI 